Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial-Reference-Cited by-同舟云学术

Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial

Published:2017-04 Issue:4 Volume:18 Page:486-499
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Middleton Gary,Palmer Daniel H,Greenhalf William,Ghaneh Paula,Jackson Richard,Cox Trevor,Evans Anthony,Shaw Victoria E,Wadsley Jonathan,Valle Juan W,Propper David,Wasan Harpreet,Falk Stephen,Cunningham David,Coxon Fareeda,Ross Paul,Madhusudan Srinivasan,Wadd Nick,Corrie Pippa,Hickish Tamas,Costello Eithne,Campbell Fiona,Rawcliffe Charlotte,Neoptolemos John P

Publisher

Elsevier BV

Subject

Oncology

Reference33 articles.

1. Pancreatic cancer;Kleeff;Nat Rev Dis Primers,2016

2. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;Conroy;N Engl J Med,2011

3. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine;Von Hoff;N Engl J Med,2013

4. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group;Moore;J Clin Oncol,2007

5. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer;Van Cutsem;J Clin Oncol,2009

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small molecular inhibitors: Therapeutic strategies for pancreatic cancer;Drug Discovery Today;2024-07

2. Anlotinib/Apatinib Plus Chemotherapy as Second-Line or Later Therapy in Advanced Osteosarcoma;2024

3. Advances in the management of pancreatic cancer;BMJ;2023-12-13

4. Therapeutic advances targeting tumor angiogenesis in pancreatic cancer: Current dilemmas and future directions;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-09

5. Addressing the Clinical Importance of Equilibrative Nucleoside Transporters in Drug Discovery and Development;Clinical Pharmacology & Therapeutics;2023-07-21